The Cholesterol You Can’t Diet Away: Lp(a) Explained

20% of the population has high Lipoprotein(a), yet most doctors don't test for it until it’s too late. Lp(a) is an independent genetic risk factor that tr…

Published November 21, 202531:50The Longevity Show

Lp(a) is the cardiovascular risk factor most likely to be high in someone with a perfectly normal lipid panel, and the one least likely to have been tested for. Dr. Lin opens with a patient whose father had a heart attack at 52 and whose own cholesterol always came back normal — the answer only appeared once Lp(a) was measured.

The episode is built around why this particle behaves differently from LDL. Lp(a) carries an extra protein, apo(a), which does three separate kinds of damage: it drives plaque formation via oxidised phospholipids, it sustains arterial inflammation, and — because apo(a) structurally resembles plasminogen — it interferes with your ability to break down clots. Three mechanisms, one particle.

The practical core is short. Levels are over 90% genetic, effectively fixed from early childhood, and essentially immovable by diet or exercise. So the test is a one-time blood draw you have to specifically request, and the response to a high result is to treat every other risk factor harder while the drug pipeline matures.

Before you watch

Lp(a) is not rare — roughly 20–30% of the global population carries an elevated level, and it is missing from standard lipid panels. Both the ACC and AHA recommend checking it at least once, but it is rarely added in primary care simply because it is not bundled into the default panel.
It is a one-time test. Levels are set by toddlerhood, over 90% genetically determined, and stay stable for life. There is no need to repeat it and no value in tracking it over time.
The thresholds discussed: 50 mg/dL (about 125 nmol/L) and above is the high-risk category, 30–50 is intermediate. Anything north of 30 is worth a serious conversation about overall cardiovascular risk — ideally early, rather than after an event.
Risk varies substantially by ancestry, which is why family history alone is an incomplete screen. Median levels run highest in Black populations (around 27 mg/dL, with 60–70% above 25) and lowest in Mexican Hispanic and East Asian populations, with South Asian and Dominican Hispanic groups in between.
The damage happens through three distinct pathways, not one. Oxidised phospholipids on Lp(a) drive endothelial dysfunction and foam cell formation; the particle sustains inflammatory signalling through IL-1β, IL-6 and TNF-α; and apo(a) acts as a decoy for plasminogen, impairing the clot breakdown that would otherwise protect you.
Lifestyle does not move the number, and that is worth accepting rather than fighting. Diet, exercise and weight loss have minimal direct effect. They remain essential — they reduce the inflammation and particle burden that determine whether elevated Lp(a) actually turns into an event — but they are managing the environment, not the gene.
Standard lipid drugs mostly miss it. Statins may raise Lp(a) slightly; niacin and ezetimibe have not delivered reliable reductions. PCSK9 inhibitors lower it 20–30% as a secondary effect, which is meaningful but not sufficient on its own if your level is high.
The RNA-based therapies are the genuine shift. Pelacarsen, an antisense oligonucleotide, has shown reductions up to 80%; siRNA agents including olpasiran up to 90%, many using GalNAc conjugation to target the liver directly. Muvalaplin is an oral small molecule that blocks assembly of the particle. None is approved yet, and trial enrolment is a real option for people with high levels.
For the highest-risk patients who have not responded to anything else, lipoprotein apheresis physically filters Lp(a) from the blood — 60–75% reduction per session, though it must be repeated and is available only at specialised centres.

Chapters

Questions

Why wasn't Lp(a) on my cholesterol panel?

Because it is not bundled into the standard panel and has to be ordered separately. Dr. Lin's read is that this is mostly logistical rather than clinical — a physician seeing 30 to 40 patients a day is unlikely to remember an add-on that isn't part of the default order set. Both the ACC and AHA recommend everyone have it checked at least once, so it is reasonable to ask for it by name, particularly with any family history of early heart disease.

Do I need to retest my Lp(a) periodically?

No. Levels are largely fixed from early childhood and over 90% genetically determined, so a single measurement tells you what you need to know for life. That is unusual among lipid markers and is one of the reasons it is worth doing early — the result changes how aggressively everything else should be managed over decades.

Can I lower Lp(a) with diet or exercise?

Not meaningfully. This is the point the episode is most emphatic about: unlike LDL or triglycerides, Lp(a) barely responds to lifestyle. A few interventions show small effects in studies — flaxseed and certain high-ALA oils in the range of 7–9%, and short-term changes with moderate alcohol — but Dr. Lin explicitly counsels against pursuing the alcohol or saturated fat angles, because the cost to blood pressure and LDL outweighs a modest Lp(a) shift. Lifestyle still matters enormously; it just works on the environment rather than the particle.

My Lp(a) is high. What should I actually do now?

Treat everything else harder. Because Lp(a) adds risk on top of the same ApoB, the targets for your other numbers should be set lower than they would otherwise be. Discuss whether a PCSK9 inhibitor is appropriate — it lowers Lp(a) 20–30% alongside a large LDL reduction. Ask about clinical trial enrolment for the RNA-based agents if your level is very high. And keep the modifiable risks — blood pressure, glucose, smoking, weight — tightly managed, since those determine whether the risk converts into an event.

What other numbers should I be looking at alongside it?

ApoB is the most useful single addition, because it counts all the harmful particles including Lp(a) — above 90 mg/dL suggests elevated risk. The episode also flags the triglyceride-to-HDL ratio, which isn't printed on most lab reports but is easy to calculate and, in some studies, predicts events and all-cause mortality better than LDL-C or non-HDL. Dr. Lin aims for a ratio under 1 in practice.

The Longevity Letter